Sarepta reports microdystrophin expression data for fourth patient in DMD gene therapy trial

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said AAVrh74.MHCK7.micro-Dystrophin led to mean sarcolemma-localized transduced microdystrophin expression, as measured by immunohistochemistry, of 81.2% and a mean fiber intensity of 96% compared with normal controls in four Duchenne muscular dystrophy (DMD) patients ages four to seven in a Phase I/IIa trial. Data

Read the full 478 word article

User Sign In